RFA-DA-23-008: Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $400,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 12, 2024.
From the official notice on Grants.gov, last changed May 17, 2022. Checked November 7, 2026.
- Award ceiling$400,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsRequired
- Funded byNIDA
- Median yearly award$600,104
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-DA-23-008 were run by National Institute on Drug Abuse (NIDA, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-23-008 in the NIH Guide.
Key dates
| Posted | May 16, 2022 |
|---|---|
| Deadline | November 12, 2024 |
| Archived by Grants.gov | December 18, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $600,104; it allows up to $400,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Stimulant use has been increasing among opioid users since 2016, based on overdose data and this makes control of the opioid epidemic more difficult, as it occurs in addition to the continuing influx of fentanyl and related compounds. Stimulant/opioid users present unfamiliar clinical issues to providers and experienced providers often find polysubstance users less motivated to address stimulant use. Stimulant use also has continued to account for a substantial fraction of HIV cases among gay men and other MSM. Much of this use is problematic/episodic (meth, cocaine, ketamine) and does not rise to the level of SUD or represents mild SUD despite problematic practices (syringe sharing, unprotected sex, etc.). We have limited tools for stimulant treatment and even fewer tools for addressing non-SUD or mild SUD stimulant use. New initiatives should incorporate new treatments as they become available. Particular attention is needed re: stimulant use in the context of polysubstance use that includes opioids including identification of motivations and contexts for more effectively implementing intervention.
Funded under RFA-DA-23-008 so far
NIH funded 2 projects under RFA-DA-23-008 in fiscal 2025 to 2026, at 2 institutions. The median yearly award was $600,104.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| RESTORE (Recovery and Engagement for STimulant users On Re-entry) | UT Southwestern Medical Center | 2026 | $624,775 |
| Hybrid Trial of Peer-Supported Affect Regulation and Contingency Management to Improve HIV Prevention Outcomes in the Southern United States | Wake Forest University Health Sciences | 2026 | $550,556 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-23-008 still open?
No. It closed on November 12, 2024.
Who can apply for Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)?
Closed November 12, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $400,000 each.
Who has been funded under RFA-DA-23-008?
NIH RePORTER lists 2 projects funded under RFA-DA-23-008 in fiscal 2025 to 2026, at 2 institutions. The most were at UT Southwestern Medical Center, Wake Forest University Health Sciences.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)